International Journal of Collaborative Research on Internal Medicine & Public Health Vol. 5 No. 8 (2013) 567 In Vitro Activity of Tigecycline against Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin resistant Enterococci (VRE) As Evaluated by Disc diffusion method and E-test Manisha Mane 1* , Nita Gangurde 2 1 M.D. (Microbiology), Associate Professor, Dept of Microbiology, ESIC MC & PGIMSR, K K Nagar, Chennai-600078, Tamil Nadu, India 2 M.D (Microbiology), Assistant Professor, Dept of Microbiology, Dr V.P. Medical College & Hospital, Nashik, Maharashtra-422003, India * Corresponding Author: Dr Manisha S. Mane M.D. (Microbiology); Associate Professor Dept of Microbiology, ESIC MC & PGIMSR, K K Nagar, Chennai-600078, Tamil Nadu, India Email: drmanishasmane@gmail.com | Cell No. +919444224860 Abstract Introduction: Tigecycline is an antibiotic belonging to the glycylcyclines class with in vitro activity against most gram positive bacteria, even multidrug resistant pathogens. It is considered to be a newer treatment option for emerging multidrug resistant pathogens. Aims & Objectives: To evaluate the in vitro activity of Tigecycline against Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) isolated from various clinical specimens to compare with other antimicrobials. Materials & Methods: A total of 75 multidrug resistant isolates of MRSA (60) and VRE (15) were tested for Tigecycline susceptibility by the E-test and disc diffusion methods. Results: Tigecycline showed good microbiological activity against all the isolates of MRSA and VRE with 100% susceptibility. Conclusion: Tigecycline was found to be highly effective against multidrug resistant MRSA & VRE. Therefore it is an alternative option for treatment of complicated skin &soft tissue and intra-abdominal infections caused by such multidrug resistant pathogens. Key words: Tigecycline, multidrug resistance, in vitro susceptibility, MRSA and VRE